CYCC — Cyclacel Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $95.76m
- $92.62m
- $0.04m
Annual income statement for Cyclacel Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.42 | 0.043 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 10.6 | 22.9 | 27.7 | 25.9 | 12 |
| Operating Profit | -10.6 | -22.9 | -27.7 | -25.5 | -12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.68 | -22.7 | -25.9 | -25.6 | -12 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.45 | -18.9 | -21.2 | -22.6 | -11.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.45 | -18.9 | -21.2 | -22.6 | -11.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.4 | -19.1 | -21.4 | -22.8 | -11.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -51.3 | -32.1 | -28.5 | -26.7 | -2.09 |
| Dividends per Share |